Ten studies from 2013 with potential to change endocrinology practice were summarized in Annals of Internal Medicine's annual Update in Endocrinology, published in the June 3 issue.
A new summary of the guideline from Kidney Disease: Improving Global Outcomes (KDIGO) highlights important points for clinicians, including recommendations about prescribing of diabetes medications.
A cohort study found a threefold increase in the risk for diabetic ketoacidosis with sodium-glucose cotransporter-2 (SGLT-2) inhibitors compared to dipeptidyl peptidase-4 (DPP-4) inhibitors, with possible variation by severity or duration of diabetes
Prior metformin use was associated with a threefold decrease in mortality from COVID-19 in one study of patients with type 2 diabetes, while three other studies found mixed results on whether dipeptidyl peptidase-4 (DPP-4) inhibitors affect COVID-19
Amputations among U.S. patients with diabetes decreased between 2000 and 2009 but increased by 50% from 2009 to 2015, leading the American Heart Association (AHA) to call for better identification and treatment of peripheral artery disease and
A recent meta-analysis from Denmark looked at patients with genetic variations that cause increases in plasma glucose levels and found that their elevated ischemic stroke risk appeared to be mitigated by treatment with certain classes of diabetes
Accordingly, the associated BMJ Rapid Recommendations will provide risk stratified recommendations and highlight the need for shared decision making to allow patients and clinicians to make well informed decisions together,” the
A small subgroup analysis of two randomized trials found that median time to resolution of diabetic ketoacidosis was 13 hours in patients who received balanced crystalloids versus nearly 17 hours in those who received saline.
The KDIGO guidelines highlight the importance of treating patients who have diabetes, hypertension, and albuminuria with an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker.
The score, which was based on cardiac troponin, N-terminal pro-B-type natriuretic peptide, C-reactive protein, and electrocardiography, could be used to target specific therapies to the highest-risk patients, study authors said.